Redeye initiates coverage of SynAct Pharma, a biotech company advancing a novel approach to controlling inflammation through resolution rather than traditional antagonism. Its lead candidate, resomelagon, is undergoing a phase IIb trial in rheumatoid arthritis designed to optimize the probability of success, with full recruitment expected by Q4 2025. Strong results could spur a partnering deal in 2026, representing a large upside to the current share price.

Read more and download the Research Report.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/